UCB Receives the EC’s Approval for Rystiggo (rozanolixizumab) for the Treatment of Adults with Generalized Myasthenia Gravis (gMG)
Shots:
- The approval was supported by the P-III (MycarinG) study evaluating the safety, efficacy & tolerability of Rystiggo (7 or 10mg/kg) vs PBO in gMG patients. The 1EP of the study includes change in MG-ADL score at Day43 & 2EPs include change in MG-C score, QMG, patient-reported outcomes at Day43 and AEs
- The trial depicted clinically meaningful & statistically significant improvement in gMG-specific outcome vs PBO as reduction in MG-ADL scores from baseline to Day43 were greater with both doses vs PBO
- Rystiggo, humanized mAb that specifically binds to human FcRn, received the EU’s ODD in 2020 for gMG. The approval came following the US FDA & MHLW’s approval for Rystiggo & Zilbrysq & EC’s approval for UCB’s Zilbrysq in 2023
Ref: UCB | Image: UCB
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
